Evotec Results Presentation Deck

evotec SMALL MOLECULES BIOLOGICS PAGE 4 DRUG DISCOVERY PLATFORM CELL & GENE THERAPY PRECLINICAL 33 ANTIS THERAPY FROPULT DISCOVERY Strong overall performance and progress in all "lanes" H1 2021 - Highlights & Lowlights Highlights • Business building accelerated, despite COVID-19 Multiple new & extended integrated drug discovery and development alliances (EVOIR&D) • J.PODⓇ 1 US in Redmond opening August 18th; construction of J.POD® 2 EU to start in Q4 2021 (EVOaccess) Acquisition of Verona site completed - Now "Campus Levi-Montalcini" BMS Oncology protein degradation partnership – significant extension ahead of term • New protein degradation collaboration in undisclosed therapeutic area also signed with BMS PRROTECT, an initiative for pandemic preparedness, launched • Confidential submission of draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering of American Depositary Shares (after period-end) • Positive Phase Ilb results for Bayer's eliapixant in patients with refractory chronic cough (RCC) (after period-end) (EVOroyalty) Lowlights Slight delays in milestones, but several important milestones imminent

View entire presentation